These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18362265)

  • 1. Responsiveness and predictive values in PPMS: an uncertain message.
    Cutter GR; Lublin FD
    Neurology; 2008 Mar; 70(13 Pt 2):1061-2. PubMed ID: 18362265
    [No Abstract]   [Full Text] [Related]  

  • 2. Responsiveness and predictive value of EDSS and MSFC in primary progressive MS.
    Kragt JJ; Thompson AJ; Montalban X; Tintoré M; Río J; Polman CH; Uitdehaag BM
    Neurology; 2008 Mar; 70(13 Pt 2):1084-91. PubMed ID: 18184917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary neopterin and nitric oxide metabolites as markers of interferon beta-1a activity in primary progressive multiple sclerosis.
    Rejdak K; Leary SM; Petzold A; Thompson AJ; Miller DH; Giovannoni G
    Mult Scler; 2010 Sep; 16(9):1066-72. PubMed ID: 20639271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
    Minden S; Hoaglin D; Jureidini S; Hadden L; Frankel D; Komatsuzaki Y; Outley J
    Mult Scler; 2008 Jun; 14(5):640-55. PubMed ID: 18566028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glatiramer acetate treatment in PPMS: why males appear to respond favorably.
    Wolinsky JS; Shochat T; Weiss S; Ladkani D;
    J Neurol Sci; 2009 Nov; 286(1-2):92-8. PubMed ID: 19426995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging therapies for relapsing multiple sclerosis.
    Cohen JA
    Arch Neurol; 2009 Jul; 66(7):821-8. PubMed ID: 19597083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-modifying treatments for progressive multiple sclerosis.
    Comi G
    Mult Scler; 2013 Oct; 19(11):1428-36. PubMed ID: 24062415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI as an outcome in multiple sclerosis clinical trials.
    Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC
    Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Primary progressive multiple sclerosis: a treatment turns out to be finally effective].
    Lalive PH
    Rev Med Suisse; 2016 Mar; 12(508):472-3. PubMed ID: 27089606
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of primary progressive multiple sclerosis.
    Kantarci O
    Semin Neurol; 2013 Feb; 33(1):74-8. PubMed ID: 23709215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The search for responsive clinical endpoints in primary progressive multiple sclerosis.
    Bosma LV; Kragt JJ; Brieva L; Khaleeli Z; Montalban X; Polman CH; Thompson AJ; Tintoré M; Uitdehaag BM
    Mult Scler; 2009 Jun; 15(6):715-20. PubMed ID: 19383646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No shortcuts to outcome in MS clinical trials?
    Koch-Henriksen N
    Neurology; 2009 Feb; 72(8):686-7. PubMed ID: 19237696
    [No Abstract]   [Full Text] [Related]  

  • 14. Factors associated with the risk of secondary progression in multiple sclerosis.
    Koch M; Uyttenboogaart M; van Harten A; De Keyser J
    Mult Scler; 2008 Jul; 14(6):799-803. PubMed ID: 18573840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary neuroprotection: the Holy Grail of multiple sclerosis therapy.
    Fox RJ
    Neurology; 2010 Mar; 74(13):1018-9. PubMed ID: 20200341
    [No Abstract]   [Full Text] [Related]  

  • 16. Primary progressive multiple sclerosis: a comparative study of the diagnostic criteria.
    de Seze J; Debouverie M; Waucquier N; Steinmetz G; Pittion S; Zephir H; Fleury M; Blanc F; Vermersch P
    Mult Scler; 2007 Jun; 13(5):622-5. PubMed ID: 17548441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary progressive multiple sclerosis : current and future treatment options.
    Leary SM; Thompson AJ
    CNS Drugs; 2005; 19(5):369-76. PubMed ID: 15907149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standards for sample composition and impairment classification in neuropsychological studies of multiple sclerosis.
    Benedict R
    Mult Scler; 2009 Jul; 15(7):777-8. PubMed ID: 19542261
    [No Abstract]   [Full Text] [Related]  

  • 20. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study.
    Calabrese M; Rocca MA; Atzori M; Mattisi I; Bernardi V; Favaretto A; Barachino L; Romualdi C; Rinaldi L; Perini P; Gallo P; Filippi M
    Neurology; 2009 Apr; 72(15):1330-6. PubMed ID: 19365054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.